Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
A/Darwin/9/2021 (H3N2) - like strain (A/Norway/16606/2021, MEDI 355293) / A/Victoria/2570/2019 (H1N1)pdm09 - like strain (A/Victoria/1/2020, MEDI 340505) / B/Austria/1359417/2021 - like strain (B/Austria/1359417/2021, MEDI 355292) / B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 306444)
AstraZeneca AB
J07BB03
influenza vaccine (live attenuated, nasal)
Influenza vaccines, Influenza, live attenuated
Influenza, Human
Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. The use of Fluenz Tetra should be based on official recommendations.
Revision: 24
Authorised
2013-12-04
21 B. PACKAGE LEAFLET 22 PACKAGE LEAFLET: INFORMATION FOR THE USER FLUENZ TETRA NASAL SPRAY SUSPENSION Influenza vaccine (live attenuated, nasal) READ ALL OF THIS LEAFLET CAREFULLY BEFORE THE VACCINE IS GIVEN BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU OR YOUR CHILD. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, nurse or pharmacist. - This vaccine has been prescribed for you or your child only. Do not pass it on to others. - If any of the side effects gets serious, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Fluenz Tetra is and what it is used for 2. What you need to know before you are given Fluenz Tetra 3. How Fluenz Tetra is given 4. Possible side effects 5. How to store Fluenz Tetra 6. Contents of the pack and other information 1. WHAT FLUENZ TETRA IS AND WHAT IT IS USED FOR Fluenz Tetra is a vaccine to prevent influenza (flu). It is used in children and adolescents 24 months to less than 18 years of age. Fluenz Tetra will help to protect against the four virus strains contained in the vaccine, and other strains closely related to them. HOW FLUENZ TETRA WORKS When a person is given the vaccine, the immune system (the body’s natural defence system) will produce its own protection against the influenza virus. None of the ingredients in the vaccine can cause the flu. Fluenz Tetra vaccine viruses are grown in chicken eggs. Each year the vaccine targets four strains of influenza, following the annual recommendations by the World Health Organisation. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN FLUENZ TETRA YOU WILL NOT BE GIVEN FLUENZ TETRA: IF YOU ARE ALLERGIC to gentamicin, gelatin or any of the other ingredients of this vaccine (listed in section 6 “Contents of the pack and other information”). if you have ever had a severe allergic reaction to eggs or egg proteins. For signs of allergic reactions, see section 4 “Poss Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Fluenz Tetra nasal spray suspension Influenza vaccine (live attenuated, nasal) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Reassortant influenza virus* (live attenuated) of the following four strains**: A/Victoria/4897/2022 (H1N1)pdm09 - like strain (A/Norway/31694/2022, MEDI 369815) 10 7.0±0.5 FFU*** A/Darwin/9/2021 (H3N2) - like strain (A/Norway/16606/2021, MEDI 355293) 10 7.0±0.5 FFU*** B/Austria/1359417/2021 - like strain (B/Austria/1359417/2021, MEDI 355292) 10 7.0±0.5 FFU*** B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 306444) 10 7.0±0.5 FFU*** .................................................................................................................per 0.2 ml dose * propagated in fertilised hens’ eggs from healthy chicken flocks. ** produced in VERO cells by reverse genetic technology. This product contains genetically modified organisms (GMOs). *** fluorescent focus units. This vaccine complies with the WHO recommendation (Northern Hemisphere) and EU decision for the 2023/2024 season. The vaccine may contain residues of the following substances: egg proteins (e.g. ovalbumin) and gentamicin. The maximum amount of ovalbumin is less than 0.024 micrograms per 0.2 ml dose (0.12 micrograms per ml). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Nasal spray, suspension The suspension is colourless to pale yellow, clear to opalescent with a pH of approximately 7.2. Small white particles may be present. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. The use of Fluenz Tetra should be based on official recommendations. 3 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Children and adolescents from 24 months:_ 0.2 ml (administered as 0.1 ml per nostril). For children who have not previously been vaccinated against seasonal influenza, a second dose should be given after an interval o Lue koko asiakirja